Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Clinical results with the Resolute zotarolimus-eluting stent in total coronary occlusions

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Feasibility and safety of transcaval transcatheter aortic valve implantation: a multicentre European registry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Impact of implant depth on hydrodynamic function of the ALLEGRA bioprosthesis in valve-in-valve interventions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The role of the Heart Team in the planning of aortic valve replacement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Will the Evolut Low Risk trial change my practice?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Validation of the all-comers design: Results of the TARGET-AC substudy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Interaction of ischaemic postconditioning and thrombectomy in patients with ST-elevation myocardial infarction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Henning Kelbæk
  • Lene Holmvang
  • Gert Richardt
  • Franz R Eberli
  • Pieter Stella
  • Pawel E Buszman
  • Franz-Josef Neumann
  • Patrick W Serruys
  • Stephan Windecker
  • Petr Widimský
  • Jorge A Belardi
  • Sigmund Silber
Vis graf over relationer

Aims: We conducted a pooled post hoc analysis (RESOLUTE All Comers and RESOLUTE International) of patients who had the Resolute® zotarolimus-eluting stent (R-ZES) implanted in revascularised total occlusions (TO) compared with patients treated with R-ZES for non-occluded lesions. Methods and results: Patients were divided into three groups: chronic TO (CTO; n=256), non-chronic TO (n=292), and no occlusion (n=2,941). Clinical and safety outcomes assessed through two years included target lesion failure (TLF: cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularisation) and Academic Research Consortium definite or probable stent thrombosis. The rate of TLF at two years was not significantly different among patients in the CTO (9.1%), TO (9.8%), and no occlusion (10.4%) groups (log-rank p=0.800); neither were the components of TLF. Definite or probable stent thrombosis occurred more frequently in the TO group (2.8% vs. 1.2% in the CTO and 1.1% in the group with no occlusion, p=0.027). There were 10 late and six very late stent thrombosis events. Conclusions: Apart from a higher rate of stent thrombosis in patients with TO, patients with totally occluded coronary arteries who receive revascularisation with an R-ZES have clinical outcomes comparable to those who receive a similar stent in non-occluded lesions.

OriginalsprogEngelsk
TidsskriftEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Vol/bind11
Udgave nummer6
Sider (fra-til)650-7
ISSN1774-024X
DOI
StatusUdgivet - 2015

ID: 45030583